The outcomes of PCI in diabetics have been suboptimal in current generational DES and have been unclear in DCB . The landmark EASTBOURNE @ 3,000 patient study, is the Worlds Largest DCB experiance in real world population using the Magic Touch SCB , viz Novel Next generational & Worlds 1st CE commercialized Sirolimus DCB. We are thankful to Dr Bernardo Cortese , Dr Antonio Colombo and the many other Globally renonwned Investigators of EASTBOURNE study. The Now published Diabetic cohort of 864 Patients with remarkable results with Magic Touch SCB having no significant increase in TLR vs Non Diabetic and more over the diabetic status , did not affect device performance in terms of TLR in both de-novo lesions & ISR . The expanding evidence of the US FDA breakthrough designated device continues to extend its favourable treatement effects accross complex occlusive vascular diseases with real world use in over 80 countries Worldwide- Confidence Inspired by Real World Use # Gamechanger Technologies # Largest & Longest Studies Clinical Program of over 23 k patients # US FDA breakthrough Designation # over 100k patients treated globally spanning over 80 countries
Which is the role of DCB in diabetic patients? Published today the subanalysis of the #EastbourneStudy in diabetic patients, by Gianluca Caiazzo Angelo Oliva et Al. #CardiovascularDiabetology Fondazione Ricerca e Innovazione Cardiovascolare DCB ACADEMY
Business Development - International Expansion - Pharmaceuticals - Healthcare - Clinical Trials Supplies - RLD/ Comparator Drugs Sourcing
8moVery impressive outcomes!